GI Malignancies and Immunotherapy

Posted On 2020-05-15 07:16:54

Gastrointestinal malignancies represent a common and heterogeneous group of tumors and account for a high percentage of adult cancers. Over the past decades, early detection, advanced endoscopy and surgery, along with the additional benefit in some cases from perioperative treatment, have led to improved outcomes in localized disease.

Immunotherapy for gastrointestinal malignancies: the journey does not end here!

Khaldoun Almhanna

Review Article
Esophageal, gastric cancer and immunotherapy: small steps in the right direction?
Adam Zayac, Khaldoun Almhanna

Colon cancer and immunotherapy—can we go beyond microsatellite instability?
Rimini Breakstone

Hepatobiliary cancers and immunotherapy: where are we now and where are we heading?
Adam Zayac, Khaldoun Almhanna

Pancreatic cancer and immune checkpoint inhibitors—still a long way to go
Jessica Bian, Khaldoun Almhanna

Review Article
Novel immunotherapy strategies for treatment of neuroendocrine neoplasms
Taymeyah Al-Toubah, Mauro Cives, Jonathan Strosberg

Anal cancer and immunotherapy—are we there yet?
Jessica J. Bian, Khaldoun Almhanna

Review Article
Immunotherapy and radiation therapy for gastrointestinal malignancies: hope or hype?
Shahed Badiyan, Adeel Kaiser, Bory Eastman, Matthew Forsthoefel, Jing Zeng, Keith Unger, Michael Chuong

Immune checkpoint inhibitors in gastrointestinal malignancies: what can we learn from experience with other tumors?
Anand B. Shah, Katelyn R. Sommerer, Khaldoun Almhanna

Finding the hot spot: identifying immune sensitive gastrointestinal tumors
Andre Luiz Pitanga Bastos De Souza

The series “GI Malignancies and Immunotherapy” was commissioned by the editorial office, Translational Gastroenterology and Hepatology without any sponsorship or funding. Khaldoun Almhanna served as the unpaid Guest Editor for the series.